Metafora Biosystems specializes in advanced technologies for single-cell analysis and metabolism profiling, utilizing artificial intelligence to enhance data analysis and clinical diagnostics. Their proprietary platform focuses on understanding cell metabolism, which is crucial for determining cell fate and function. The company offers innovative in vitro diagnostics (IVDs) and cell therapy reagents that enable the monitoring of cellular fitness and metabolic states. Their flagship product, METAglut1, is designed for early testing of various phenotypes related to metabolic disorders, showcasing the company's commitment to improving patient outcomes through precise diagnostics.

Additionally, Metafora's METAflow software provides an "augmented intelligence" solution that streamlines flow and mass cytometry analysis, delivering quick, objective, and reproducible results for both research and clinical applications. The company is actively engaged in collaborations with medical researchers and patient associations to ensure their solutions address unmet clinical needs. Their ongoing projects, such as the cellMETA-analyzer, aim to merge innovative biology with data science to detect and characterize tumor cells, further solidifying Metafora's role in advancing healthcare through cutting-edge technology.

France

At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. 

We are passionate about cell biology.

We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health.

Metafora Biosystems

Company Details